Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
For RRMM participants who have received at least one prior line of therapy (LoT) for MM:
Have documented progression from a prior LoT
Participants who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
IMiDs
PIs
Combination of IMiD + PI
Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
For NDMM participants receiving frontline therapy:
Eligible to receive frontline therapy for MM (no prior MM treatment)
Participants who have initiated treatment for MM with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
IMiDs
PIs
Combination of IMiD + PI
Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
You may not be if
Participants who are currently participating in a clinical trial for MM
Participants who are currently receiving treatment for primary cancer other than MM
Participants who are not willing or able to provide informed consent
Participants who are incarcerated
Participants under compulsory detention for treatment of a physical (eg, infectious) or psychiatric illness
Clareo Health | Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
